In the management of traumatic hyphaema, should pupil‑dilating (cycloplegic) anticholinergic drops be avoided to keep the iris stable and reduce the risk of re‑bleeding?

Cycloplegics Should Be Used, Not Avoided, in Traumatic Hyphema Management

The statement is INACCURATE—cycloplegic (pupil-dilating) drops should routinely be used in traumatic hyphema management, not avoided. The evidence consistently supports their use as standard therapy.

Evidence-Based Recommendation

Multiple sources confirm that topical cycloplegics (such as atropine) are a cornerstone of hyphema management 1, 2, 3. The rationale is to:

• Reduce pain and photophobia by paralyzing the ciliary muscle
• Stabilize the blood-aqueous barrier and reduce inflammation
• Prevent posterior synechiae formation
• Provide comfort during the healing period

Why the Concern About Pupil Dilation is Misplaced

The theoretical concern that pupil dilation might increase rebleeding risk by causing iris movement is not supported by clinical evidence. In fact:

• No studies demonstrate increased rebleeding with cycloplegic use 4, 5
• The Cochrane systematic review (2019) examining 27 trials with 2,643 participants found no evidence that cycloplegics affect secondary hemorrhage rates 4
• The benefit of reducing inflammation and providing comfort outweighs any theoretical mechanical concerns

What Actually Reduces Rebleeding Risk

The evidence shows that antifibrinolytic agents (not avoiding cycloplegics) reduce secondary hemorrhage:

• Systemic aminocaproic acid reduces rebleeding (RR 0.28,95% CI 0.13-0.60) 4
• Tranexamic acid significantly reduces secondary hemorrhage (RR 0.31,95% CI 0.17-0.55) 4
• Cycloplegics showed no effect on rebleeding rates in either direction 4, 5

Standard Treatment Protocol

The recommended approach includes 1, 2:

• Topical cycloplegics (atropine or cyclopentolate)
• Topical corticosteroids to reduce inflammation
• Rigid eye shield for protection
• Activity restriction (quiet ambulation)
• Antifibrinolytic agents (systemic aminocaproic acid or tranexamic acid) to prevent rebleeding
• Avoid aspirin and NSAIDs (these actually increase bleeding risk)

Common Pitfall to Avoid

Do not withhold cycloplegics based on unfounded concerns about iris movement. The real risks in hyphema management are:

1. Secondary hemorrhage (3-5 days post-injury)—prevented by antifibrinolytics, not by avoiding cycloplegics
2. Elevated intraocular pressure—requires antiglaucoma medications
3. Corneal blood staining—occurs with large hyphemas and elevated IOP
4. Optic atrophy—from prolonged pressure elevation

None of these complications are increased by appropriate cycloplegic use 4, 1.